Reports Q2 revenue $1.85M, consensus $790,000. “The past 12 months have been transformative for the company,” said Marc Hedrick, president and CEO of Plus Therapeutics. “We now have two lead indications, recurrent glioblastoma and leptomeningeal metastases, for our rhenium (186Re) obisbemeda investigational drug and we plan to fully leverage available external third-party funding to move both clinical development programs through Phase 2 and evaluate accelerated approval opportunities.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PSTV:
- Plus Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
- Is PSTV a Buy, Before Earnings?
- Plus Therapeutics reports positive Phase 1 trial data of rhenium obisbemeda
- Plus Therapeutics Reports ReSPECT-LM Phase 1 Trial Data at the 2023 SNO/ASCO CNS Cancer Conference
- Plus Therapeutics files to sell 1.5M shares of common stock for holders